Production Capacity and Resource Matching - The company has six production bases located in Shanghai, Hefei, Hengyang, Zhengzhou, Wenzhou, and Nanning, with Shanghai, Hefei, and Hengyang being the largest [2] - Current production capacity matches the plasma collection volume, with ongoing expansion projects, such as the Shanghai base, designed to increase capacity to over 1,500 tons per year [2] Plasma Station and Resource Development - Prior to the acquisition of Nanyue Biological, the company had a total of 44 plasma collection stations, with Nanyue adding 9 more, distributed across 11 provinces [3] - The company focuses on both optimizing existing plasma stations and expanding new ones to ensure continuous growth in plasma collection [4] Market Conditions and Product Demand - The blood product market currently has a certain level of inventory among companies and distributors [5] - Sales of human albumin have slightly slowed due to healthcare policies and supply-demand dynamics, but there remains a rigid demand for its various medical applications [6] Pricing and Innovation - Blood product prices have experienced slight changes influenced by policy and supply-demand factors, with the company monitoring market dynamics to maintain reasonable pricing [7] - The company is committed to innovation, focusing on both "plasma expansion" and "plasma extraction," with ongoing clinical research on SR604 injection, currently in Phase IIb trials [8] Strategic Partnerships - In March 2019, the company signed an exclusive strategic cooperation agreement with Klibor, leading to collaborative efforts in quality management and product distribution, positively impacting performance [9]